MedTrace Logo

Effects of Lutein in Retinitis Pigmentosa

NCT00029289 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2006-08-18

No results posted yet for this study

Summary

Phase I/II double-masked, randomized, placebo-controlled, cross-over trial to determine effects of lutein on vision in retinitis pigmentosa, including safety and effective dosage assessment

Conditions

Interventions

DRUG

Lutein (10 or 30 mg/day) capsules

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    lead NIH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Completion
2002-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00029289 on ClinicalTrials.gov